Palisade Bio (NASDAQ:PALI) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Palisade Bio (NASDAQ:PALI – Get Free Report) announced its earnings results on Tuesday. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.01), FiscalAI reports.

Palisade Bio Stock Performance

PALI stock opened at $1.17 on Thursday. Palisade Bio has a 52 week low of $1.08 and a 52 week high of $2.85. The company has a market capitalization of $203.90 million, a PE ratio of -2.44 and a beta of 1.61. The company’s 50-day simple moving average is $1.52 and its 200 day simple moving average is $1.82.

Analyst Ratings Changes

PALI has been the topic of several research analyst reports. Raymond James Financial started coverage on shares of Palisade Bio in a report on Thursday, October 8th. They issued an “outperform” rating and a $6.00 price target on the stock. HC Wainwright reduced their price objective on Palisade Bio to $5.00 and set a “buy” rating for the company in a report on Wednesday. Wall Street Zen downgraded Palisade Bio from a “hold” rating to a “sell” rating in a research report on Saturday, October 17th. Oppenheimer reiterated an “outperform” rating on shares of Palisade Bio in a research note on Wednesday, October 21st. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Palisade Bio in a research note on Monday, October 12th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $9.00.

View Our Latest Stock Report on PALI

About Palisade Bio

(Get Free Report)

Palisade Bio is a clinical-stage biopharmaceutical company developing therapies for gastrointestinal diseases, with a focus on oral treatments for inflammatory bowel conditions. Its pipeline includes PALI-2108, an investigational, gut-targeted PDE4 inhibitor being developed for ulcerative colitis and fibrostenotic Crohn’s disease. The company has also developed LB1148, an investigational serine protease inhibitor studied for its potential to support bowel function and reduce complications after abdominal surgery.

Featured Stories

Earnings History for Palisade Bio (NASDAQ:PALI)

Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.